EZH2 and breast carcinoma: To validate that EZH2-induced breast cancer bone metastasis outgrowth is independent of its methyltransferase function, a group of mice was treated with EZH2 methyltransferase inhibitor GSK126 (100 mg/kg, once a day, i.p. injection).